Last reviewed · How we verify
GnRH antagonists — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
GnRH antagonists (GnRH antagonists) — Novartis Pharmaceuticals.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GnRH antagonists TARGET | GnRH antagonists | Novartis Pharmaceuticals | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GnRH antagonists CI watch — RSS
- GnRH antagonists CI watch — Atom
- GnRH antagonists CI watch — JSON
- GnRH antagonists alone — RSS
Cite this brief
Drug Landscape (2026). GnRH antagonists — Competitive Intelligence Brief. https://druglandscape.com/ci/gnrh-antagonists. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab